Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 68, 413-430

Update on Alzheimer's Disease Therapy and Prevention Strategies

Affiliations
Review

Update on Alzheimer's Disease Therapy and Prevention Strategies

W Vallen Graham et al. Annu Rev Med.

Abstract

Alzheimer's disease (AD) is the primary cause of age-related dementia. Effective strategies to prevent and treat AD remain elusive despite major efforts to understand its basic biology and clinical pathophysiology. Significant investments in therapeutic drug discovery programs over the past two decades have yielded some important insights but no blockbuster drugs to alter the course of disease. Because significant memory loss and cognitive decline are associated with neuron death and loss of gray matter, especially in the frontal cortex and hippocampus, some focus in drug development has shifted to early prevention of cellular pathology. Although clinical trial design is challenging, due in part to a lack of robust biomarkers with predictive value, some optimism has come from the identification and study of inherited forms of early-onset AD and genetic risk factors that provide insights about molecular pathophysiology and potential drug targets. In addition, better understanding of the Aβ amyloid pathway and the tau pathway-leading to amyloid plaques and neurofibrillary tangles, respectively, which are histopathological hallmarks of AD-continues to drive significant drug research and development programs. The main focus of this review is to summarize the most recent basic biology, biochemistry, and pharmacology that serve as a foundation for more than 50 active advanced-phase clinical trials for AD prevention and therapy.

Keywords: amyloid; cognitive impairment; dementia; neurodegeneration; neurofibrillary tangle; plaque.

Similar articles

  • Disease-modifying Drugs in Alzheimer's Disease
    L Ghezzi et al. Drug Des Devel Ther 7, 1471-8. PMID 24353405. - Review
    Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of dementia. The early stages of AD are characterized by short-term memo …
  • Immunotherapy Against Amyloid Pathology in Alzheimer's Disease
    D Galimberti et al. J Neurol Sci 333 (1-2), 50-4. PMID 23299047. - Review
    The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. …
  • New Treatment Strategies for Alzheimer's Disease: Is There a Hope?
    I Aprahamian et al. Indian J Med Res 138 (4), 449-60. PMID 24434253. - Review
    Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, and corresponds to the most common cause of dementia worldwide. Although not fully u …
  • An Update on Drug Treatment Options of Alzheimer's Disease
    M Allgaier et al. Front Biosci (Landmark Ed) 19, 1345-54. PMID 24896354. - Review
    Alzheimer's disease (AD) is characterized by progressive decrease in cognitive function and loss of short-term memory known to be associated with a dysfunction of the cho …
  • [Therapy of Alzheimer Disease]
    T Kovács. Neuropsychopharmacol Hung 11 (1), 27-33. PMID 19731816. - Review
    Dementia is one of the most important health problems in the aging populations. The most frequent cause of it is Alzheimer's disease (AD) which is characterized by intrac …
See all similar articles

Cited by 59 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback